These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 35877765)

  • 21. Vonoprazan and amoxicillin dual therapy as the first-line treatment of Helicobacter pylori infection: A systematic review and meta-analysis.
    Du RC; Hu YX; Ouyang Y; Ling LX; Xu JY; Sa R; Liu XS; Hong JB; Zhu Y; Lu NH; Hu Y
    Helicobacter; 2024; 29(1):e13039. PubMed ID: 38036941
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line
    Suzuki S; Gotoda T; Kusano C; Ikehara H; Ichijima R; Ohyauchi M; Ito H; Kawamura M; Ogata Y; Ohtaka M; Nakahara M; Kawabe K
    Gut; 2020 Jun; 69(6):1019-1026. PubMed ID: 31915235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of Vonoprazan for Helicobacter pylori Eradication.
    Kiyotoki S; Nishikawa J; Sakaida I
    Intern Med; 2020 Jan; 59(2):153-161. PubMed ID: 31243237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vonoprazan-amoxicillin dual therapy for
    Huang XP; Liu YJ; Lin SW; Shao YF; Qiu F; Qiu QW; Xu ZK; Chen JX; Chen LH; Lin ZQ; Dai WH; Zhang MQ; Jiang Q; Xiao ZQ; Cheng XX; Zhang XF; You WB; Chen W; Li LQ; Lin WX; Wang YF; Lai FJ; Chen LQ; Huang ZH; Zheng WQ; Wei JQ; Lin ZH
    World J Gastroenterol; 2024 Jul; 30(27):3304-3313. PubMed ID: 39086752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of a new rifabutin-based triple therapy with vonoprazan for refractory Helicobacter pylori infection: A prospective single-arm study.
    Hirata Y; Yamada A; Niikura R; Shichijo S; Hayakawa Y; Koike K
    Helicobacter; 2020 Oct; 25(5):e12719. PubMed ID: 32602161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy.
    Qian HS; Li WJ; Dang YN; Li LR; Xu XB; Yuan L; Zhang WF; Yang Z; Gao X; Zhang M; Li X; Zhang GX
    Am J Gastroenterol; 2023 Apr; 118(4):627-634. PubMed ID: 36729890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori.
    Bunchorntavakul C; Buranathawornsom A
    J Gastroenterol Hepatol; 2021 Dec; 36(12):3308-3313. PubMed ID: 34622504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.
    Tanabe H; Yoshino K; Ando K; Nomura Y; Ohta K; Satoh K; Ichiishi E; Ishizuka A; Otake T; Kohgo Y; Fujiya M; Okumura T
    Ann Clin Microbiol Antimicrob; 2018 Jun; 17(1):29. PubMed ID: 29950163
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vonoprazan With Amoxicillin or Amoxicillin and Clarithromycin for the Treatment of
    Liu L; Nahata MC
    Ann Pharmacother; 2023 Oct; 57(10):1185-1197. PubMed ID: 36688309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ten-Day Vonoprazan-Amoxicillin Dual Therapy vs Standard 14-Day Bismuth-Based Quadruple Therapy for First-Line Helicobacter pylori Eradication: A Multicenter Randomized Clinical Trial.
    Yan TL; Wang JH; He XJ; Zhu YB; Lu LJ; Wang YJ; Wang ZW; Gao JG; Xu CF; Ma H; Luan SM; Li L; Chen Y
    Am J Gastroenterol; 2024 Apr; 119(4):655-661. PubMed ID: 37975609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy.
    Ozaki H; Harada S; Takeuchi T; Kawaguchi S; Takahashi Y; Kojima Y; Ota K; Hongo Y; Ashida K; Sakaguchi M; Tokioka S; Sakamoto H; Furuta T; Tominaga K; Higuchi K
    Digestion; 2018; 97(3):212-218. PubMed ID: 29393194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eradication rates of Helicobacter pylori in treatment-naive patients following 14-day vonoprazan-amoxicillin dual therapy: A multicenter randomized controlled trial in China.
    Hu J; Mei H; Su NY; Sun WJ; Zhang DK; Fan LL; He P; Pan J; Wang XW; Zou PY; Liu YX; Guo Y; Lan CH
    Helicobacter; 2023 Aug; 28(4):e12970. PubMed ID: 37160689
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic efficacy and drug safety comparison of one-week Vonoprazan triple therapy with two-weeks Esomeprazole triple therapy in Helicobacter pylori infection: Findings from a single-centre randomized clinical trial in population of Pakistan.
    Waqar F; Noor M; Haider E; Farhat K; Ali S; Fatime Gilani SF
    J Pak Med Assoc; 2024 Mar; 74(3):432-435. PubMed ID: 38591272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children.
    Kusano C; Gotoda T; Suzuki S; Ikehara H; Moriyama M
    J Gastroenterol; 2018 Jun; 53(6):718-724. PubMed ID: 29110085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vonoprazan-Amoxicillin Dual Therapy With Different Amoxicillin Administration Regimens for Helicobacter pylori Treatment: A Randomized Controlled Trial.
    Qiu S; Huang Y; Chen J; Guo Y; Li M; Ding Z; Liang X; Lu H
    Helicobacter; 2024; 29(4):e13118. PubMed ID: 39087868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vonoprazan-amoxicillin dual therapy with different amoxicillin dosages for treatment-naive patients of Helicobacter pylori infection in China: a prospective, randomized controlled study.
    Liu Z; Sun D; Kou L; Jia L; Hao J; Zhou J; Zheng W; Gao F; Chen X
    Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):712-719. PubMed ID: 38526917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication.
    Ang D; Koo SH; Chan YH; Tan TY; Soon GH; Tan CK; Lin KW; Krishnasamy-Balasubramanian JK; Wong YJ; Kumar R; R R; Tan Y; Ong PJ; Tan YJ; Li JW; Kwek AB; Ang TL
    Aliment Pharmacol Ther; 2022 Aug; 56(3):436-449. PubMed ID: 35665947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Study on the Eradication of Helicobacter pylori by Vonoprazan Combined with Amoxicillin for 10-Day Dual Therapy.
    Yan K; Dai X; Li Z; Rong W; Chen L; Diao X
    Clin Pharmacol Drug Dev; 2024 Mar; 13(3):240-247. PubMed ID: 38197874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The safety and effectiveness of vonoprazan-based
    Ashida K; Honda Y; Sanada K; Takemura Y; Sakamoto S
    Expert Opin Drug Saf; 2019 Dec; 18(12):1255-1261. PubMed ID: 31646920
    [No Abstract]   [Full Text] [Related]  

  • 40. Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance.
    Matsumoto H; Shiotani A; Katsumata R; Fujita M; Nakato R; Murao T; Ishii M; Kamada T; Haruma K; Graham DY
    Dig Dis Sci; 2016 Nov; 61(11):3215-3220. PubMed ID: 27659671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.